Anavex/$AVXL
1D1W1MYTD1Y5YMAX
Capital at risk
About Anavex
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
- Ticker
- $AVXL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 34
- Headquarters
- New York, United States
- Website
- www.anavex.com
Anavex Metrics
BasicAdvanced
$219M
-
-$0.14
1.14
-
Price and volume
Market cap
$219M
Beta
1.14
52-week high
$10.38
52-week low
$2.26
Average daily volume
752K
Financial strength
Current ratio
15.619
Quick ratio
15.512
Profitability
Effective tax rate (TTM)
-0.14%
Management effectiveness
Return on assets (TTM)
-9.70%
Return on equity (TTM)
-12.80%
Valuation
Price to book
1.95
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-7.257
Free cash flow yield (TTM)
-13.78%
Free cash flow per share (TTM)
-0.325
Growth
Earnings per share change (TTM)
-74.50%
3-year earnings per share growth (CAGR)
-39.58%
10-year earnings per share growth (CAGR)
-9.87%
What the Analysts think about Anavex
Analyst ratings (Buy, Hold, Sell) for Anavex stock.
Analyst projections of the future price of Anavex stock.
Anavex Financial Performance
Revenues and expenses
Anavex Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Anavex
AllUSDGBPEUR
Fund name | Fund size | $AVXL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.